Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

Shah, Nisargbhai; Kris, Mark G.; Pao, William; Tyson, Leslie B.; Pizzo, Barbara; Heinemann, Murk Hein; Ben-Porat, Leah; Sachs, Dana L.; Heelan, Robert T.; Miller, Vincent A.

doi:10.1200/jco.2005.04.057

Cited by 176 publications

(118 citation statements)

References 37 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the presence of a skin rash has been associated with an improvement in response rate and survival [58]. Less commonly seen skin toxicity associated with EGFR-targeted therapy include: pruritus, dry skin, skin fissures, desquamation, and nail and cuticle cracking [59].…”

Section: Side Effects Of Agents That Target the Egfr/her Pathwaymentioning

confidence: 99%

Targeting the EGFR Pathway for Cancer Therapy

Johnston¹,

Navaratnam²,

Pitz³

et al. 2006

CMC

173

116

View full text Add to dashboard Cite

Abstract:Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies. Additionally, in most patients with multiple myeloma, the malignant cells over-express a number of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biology of this disease. These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy. Below we discuss various aspects of EGFR-targeted therapies mainly in hematologic malignancies, lung cancer and breast cancer. Beside novel therapeutic approaches, we also discuss specific side effects associated with the therapeutic inhibition of components of the EGFR-pathways. Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, ZD1839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab / Herceptin, Pertuzumab / Omnitarg / rhuMab-2C4, Cetuximab / Erbitux / IMC-C225, Panitumumab / Abenix / ABX-EGF, and also ZD6474). In addition, we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.

show abstract

Section: Side Effects Of Agents That Target the Egfr/her Pathwaymentioning

confidence: 99%

Targeting the EGFR Pathway for Cancer Therapy

Johnston¹,

Navaratnam²,

Pitz³

et al. 2006

CMC

173

116

View full text Add to dashboard Cite

show abstract

“…Trimming and epilation of the elongated eyelashes are the most common and safe therapeutic options used by patients experiencing drug-associated eyelash trichomegaly (4,15,17,26). In conclusion, trichomegaly is a rare, EGFR TKI-associated effect.…”

Section: A B C Dmentioning

confidence: 94%

“…Although trichomegaly is not a drug-limiting side effect, it can obscure vision and has been reported to cause corneal problems, including erosions (26), irritation (15,26), infection and ulcers (17). Trimming and epilation of the elongated eyelashes are the most common and safe therapeutic options used by patients experiencing drug-associated eyelash trichomegaly (4,15,17,26).…”

Section: A B C Dmentioning

confidence: 99%

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

Abstract. Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.

show abstract

“…Inhibition of EGFR mutants leads to increased cell death mediated by an apoptotic pathway that is dependent upon Bim, a Bcl-2 family member that is pro-apoptotic and regulated by Erk signaling (Costa et al, 2008;Cragg, Kuroda, Puthalakath, Huang, & Strasser, 2007;Deng et al, 2007;Gong et al, 2007). Although most patients tolerate erlotinib and gefitinib, some patients experience serious side effects such as diarrhea, rash, nausea and interstitial lung disease (Makris et al, 2007;Shah et al, 2005;Shepherd et al, 2005). Patients may have primary resistance due to EGFR drug-resistant mutations, such as EGFRvIII, which is a constitutively active form of EGFR caused by the deletion of exons 2 -7 (Greulich et al, 2005;Inukai et al, 2006;Maheswaran et al, 2008;Prudkin, Tang, & Wistuba, 2009;Wu et al, 2008), mutations in downstream signaling pathways that co-occur with EGFR mutations, such as the PI3K catalytic subunit, PIK3CA (Kawano et al, 2006), or mutations that occur in other downstream genes, such as k-Ras and b-Raf (Brose et al, 2002;Linardou www.intechopen.com et al, 2008;Mok et al, 2009;Pao et al, 2005b;Wheeler, Dunn, & Harari, 2010;.…”

Section: Use Of Egfr Inhibitors For the Treatment Of Nsclcmentioning

confidence: 99%